Elsevier

Vaccine

Volume 23, Issue 31, 1 July 2005, Pages 4070-4074
Vaccine

The effectiveness of the mumps component of the MMR vaccine: a case control study

https://doi.org/10.1016/j.vaccine.2004.10.020Get rights and content

Abstract

In 1998/1999, an outbreak of mumps occurred among children of a religious community in North East London. A case control study was conducted to assess the effectiveness of the mumps component of the MMR vaccine. One hundred and sixty-one cases of mumps were identified and 192 controls were selected. Fifty-one percent of cases and 77% of controls had a history at least one MMR vaccination. The observed effectiveness of any MMR vaccination adjusted for age, sex and general practice was 69% (95% CI: 41–84%). This is consistent with the results of other observational studies of mumps containing vaccines, but lower than the immunogenicity of mumps vaccines reported by clinical trials. This discrepancy is because observational studies tend to underestimate vaccine effectiveness, and because immunogenicity is not necessarily an accurate biological marker of vaccine effectiveness. Two doses of vaccine were more effective (88% (95% CI: 62–96%)) than a single dose (64% (95% CI: 40–78%)). The current two-dose vaccination programme remains the best method for controlling mumps infection in the community.

Introduction

Mumps is a potentially serious viral infection, the incidence of which has declined dramatically since the introduction of the MMR vaccine in October 1988. In England and Wales the number of notified cases fell from 20,713 in 1989 to 1587 in 1998 [2], and similarly dramatic declines in have followed the introduction of mumps vaccines in the US [3], Sweden [4] and Finland [5]. However, outbreaks of mumps occur where vaccination coverage is low. Mumps has re-emerged as an important infection of childhood and early adulthood as uptake of the MMR vaccine has fallen in England and Wales [2], [6], [7].

Between June 1998 and May 1999, an outbreak of mumps occurred in North East London due to genotype C virus, thought to have been imported from abroad [1]. As the outbreak became apparent, the local Consultant in Communicable Disease Control (CCDC) wrote to all local general practitioners (GPs) to encourage statutory notifications of clinical cases of mumps. Of the 144 cases notified, 142 were children of a single religious community and were notified by two general practices, A and B, which served this community. The community was concentrated into a relatively small geographical area and had its own schools and amenities. MMR vaccination coverage was low, between 67 and 86%. A case control study was conducted to identify unreported cases and to assess the effectiveness of the mumps component of the MMR vaccine.

Section snippets

Selection of cases and controls

A case was defined as a clinical or laboratory diagnosis of mumps with date of onset from 18 June 1998 to 2 May 1999. All cases in children aged between 1 and 18 years old from the religious community were included. Cases were identified in three ways. Firstly from statutory notifications of mumps from general practices A and B to the local CCDC. Secondly from searches of the electronic practice lists. Both practices used the EMIS system and patients’ notes were updated following all

Results

A total of 161 cases aged between 1 and 18 years were identified with dates of onset during the outbreak period (Fig. 1). One hundred and forty-two cases were notified by general practices A and B, 12 were identified through electronic searches of the practice lists, and seven were reported by parents. Forty-three (30.3%) of the notified cases were confirmed in the laboratory by IgM radio immunoassay, detection of mumps RNA by PCR, or both. Six cases (3.7%) of complications associated with

Discussion

The mumps component of the MMR vaccine used in the UK, which contains the Jeryl Lyn strain, is generally accepted to confer protection to around 90% of recipients [8]. This figure is based mainly on trials that have examined the immunogenicity of mumps vaccines [9], [10], [11], [12]. Observational studies conducted during mumps outbreaks have generally found the effectiveness of mumps vaccines to be lower. Our observed vaccine effectiveness of 64% for a single dose of MMR is similar to the

Acknowledgements

Dr. Bernard Cohen, HPA-CDSC, 61 Colindale Avenue, London, NW9 5EQ. All staff of the two General Practices who contributed data to the study.

References (31)

  • W.C. Sugg et al.

    Field evaluation of live virus mumps vaccine

    J Pediatr

    (1968)
  • B.S. Hersh et al.

    Mumps outbreak in a highly vaccinated population

    J Pediatr

    (1991)
  • B. Lopez Hernandez et al.

    An epidemic of mumps: a study of vaccine efficacy

    Atencion Primaria

    (2000)
  • C.A. Van den Bosch et al.

    Mumps outbreak confined to a religious community

    Eurosurveillance

    (2000)
  • Health Protection Agency. Mumps Notifications, by Sex 1989–2003....
  • Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella...
  • M. Bottiger et al.

    Swedish experience of two dose vaccination programme aimed at eliminating measles, mumps and rubella in Sweden

    BMJ

    (1987)
  • H. Peltola et al.

    The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program

    NEJM

    (1994)
  • E.A. Reaney et al.

    Mumps outbreak among young people in Northern Ireland

    Commun Dis Public Health

    (2001)
  • R.N. Pugh et al.

    An outbreak of mumps in the metropolitan area of Walsall, UK

    Int J Infect Dis

    (2002)
  • Immunisation against infectious disease. The Green Book. Department of Health;...
  • R.E. Weibel et al.

    Live attenuated mumps virus vaccine: clinical and serological aspects in a field trial

    NEJM

    (1967)
  • P.A. Brunell et al.

    Evaluation of a live attenuated mumps vaccine (Jeryl Lynn)

    Am J Dis Child

    (1969)
  • T. Vesikari et al.

    Evaluation in young children of the Urabe am 9-strain of live attenuated mumps vaccine in comparison with the Jeryl Lynn strain

    Acta Paediatr Scand

    (1983)
  • M.R. Hilleman et al.

    Live, attenuated mumps virus vaccine: protective efficacy as measured in a field evaluation

    NEJM

    (1967)
  • Cited by (0)

    View full text